Ajay Kundra

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

John H. Strickler, Andrea Cercek, Salvatore Siena et al. · The Lancet Oncology · 2023 · 217 citations

Oncology, Medicine, Pathology +7

Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm

Jen C. Wang, Ajay Kundra, Mirela Andrei et al. · Leukemia Research · 2016 · 63 citations

Hematological Malignancy, Hematology, Myeloid-derived Suppressor Cells +4

Immune Derangements in Patients with Myelofibrosis: The Role of Treg, Th17, and sIL2Rα

Jen C. Wang, Hemant Sindhu, Chi Chen et al. · PLoS ONE · 2015 · 33 citations · Full text

Immunodeficiencies, T-regulatory Cell, Immune Regulation +24

Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms

Jen C. Wang, Chi Chen, Ajay Kundra et al. · Leukemia Research · 2019 · 28 citations

Hematological Malignancy, Immunology, Cell Death +4

Programmed Cell Death Receptor (PD-1), PD-1 Ligand (PD-L1) Expression and Myeloid Derived Suppressor Cells (MDSC) In Myeloid Neoplasms Implicate The Mechanism Of IMiD Treatment Of Myelofibrosis

Ajay Kundra, Stacey Baptiste, Chi Chen et al. · Blood · 2013 · 11 citations